Please log in for more information
Access to rapid and easy-to-use molecular diagnostic tests is essential to understand individual cancer-driving gene mutations in mCRC, opening doors to timely cancer treatment decision-making. Liquid biopsy tests1 have demonstrated clear benefits as these tests are minimally invasive, fast and easy to perform compared to more traditional tumor tissue-based testing. The IdyllaTM ctKRAS Mutation Assay (RUO) and the IdyllaTM ctNRAS-BRAF-EGFR S492R Mutation Assay (RUO), operating on Biocartis’ molecular diagnostics IdyllaTM platform, are fully automated sample-to-result assays that require only 1 ml of plasma, take less than 1 minute hands-on time and have a turnaround time of approximately 2 hours each. The IdyllaTM ctKRAS Mutation Assay (RUO) is intended for the semi-quantitative and sensitive detection of 21 mutations in the KRAS gene. The IdyllaTM ctNRAS-BRAF-EGFR S492R Mutation Assay (RUO) is intended for the semi-quantitative and sensitive detection of 25 mutations (18 NRAS mutations, 5 BRAF mutations and 2 EGFR S492R mutations) 1. Diaz and Bardelli, Liquid Biopsies: Genotyping Circulating Tumor DNA. J clin Oncol (2014) 32: 579-586.
Company Information:
Biocartis is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis’ proprietary MDx IdyllaTM platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the IdyllaTM platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers eight oncology tests and two infectious disease tests.Press Photo Library available here. Follow us on Twitter: @Biocartis_.
Contact Information:
Biocartis NVGeneraal de Wittelaan 11 B3
2800 Mechelen
Belgium
Phone: +32 15 632 600
Email: info@biocartis.com
